Alliancebernstein L.P. Akebia Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 77,640 shares of AKBA stock, worth $149,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,640

Previous 77,640 -0.0%

Holding current value

$149,845

Previous $79,000 29.11%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.86 - $1.63 $66,770 - $126,553	77,640 New	77,640 $79,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $48,107 - $100,724	-150,335 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $504 - $2,051	700 Added 0.47%	150,335 $108,000
Q2 2021 Jul 30, 2021	BUY	$2.83 - $4.2 $234,324 - $347,760	82,800 Added 123.89%	149,635 $567,000
Q4 2020 Feb 08, 2021	SELL	$2.22 - $3.78 $237,919 - $405,106	-107,171 Reduced 61.59%	66,835 $187,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $10,277 - $56,244	-4,300 Reduced 2.41%	174,006 $437,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $370,098 - $753,513	55,487 Added 45.18%	178,306 $2.42 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $36,900 - $72,450	9,000 Added 7.91%	122,819 $594,000
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $23,798 - $38,403	4,399 Added 4.02%	113,819 $932,000
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $310,571 - $527,223	57,620 Added 111.24%	109,420 $605,000
Q2 2018 Aug 13, 2018	BUY	$9.15 - $11.34 $78,690 - $97,524	8,600 Added 19.91%	51,800 $517,000
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $564,192 - $849,744	43,200	43,200 $850,000

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $355M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Akebia Therapeutics, Inc. Transaction History